Morgan Stanley Maintains Overweight on Sempra, Lowers Price Target to $104

Benzinga Newsdesk www.benzinga.com Negative 78.9%

Neg 78.9% Neu 0% Pos 0%

Morgan Stanley analyst David Arcaro maintains Sempra (NYSE:SRE) with a Overweight and lowers the price target from $105 to $104.